Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
- DOI
- 10.1002/1878-0261.12933
- Published
- 2021 Sep
- Container
- Molecular oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/1878-0261.12933,
title = {Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.},
author = {Boerrigter E and Benoist GE and van Oort IM and Verhaegh GW and van Hooij O and Groen L and Smit F and Oving IM and de Mol P and Smilde TJ and Somford DM and Mehra N and Schalken JA and van Erp NP},
year = {2021},
journal = {Molecular oncology},
doi = {10.1002/1878-0261.12933},
url = {https://doi.org/10.1002/1878-0261.12933}
}RIS
TY - JOUR TI - Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. AU - Boerrigter E AU - Benoist GE AU - van Oort IM AU - Verhaegh GW AU - van Hooij O AU - Groen L AU - Smit F AU - Oving IM AU - de Mol P AU - Smilde TJ AU - Somford DM AU - Mehra N AU - Schalken JA AU - van Erp NP PY - 2021 JO - Molecular oncology DO - 10.1002/1878-0261.12933 UR - https://doi.org/10.1002/1878-0261.12933 ER -
APA
E, B., GE, B., IM, V. O., GW, V., O, V. H., L, G., F, S., IM, O., P, D. M., TJ, S., DM, S., N, M., JA, S., & NP, V. E. (2021). Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.. Molecular oncology. https://doi.org/10.1002/1878-0261.12933
Source records
- pubmed · retrieved 2026-09-25T19:34:16.679Z